Lineage Cell Therapeutics (LCTX) Misses Q2 EPS by 1c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q2 EPS of ($0.03), $0.01 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $1.07 million versus the consensus estimate of $4.57 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• Microsoft plans data center push to triple its computing power - Bloomberg
• Wedbush Assumes Tenable (TENB) at Underperform
• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance